<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828083</url>
  </required_header>
  <id_info>
    <org_study_id>1617319</org_study_id>
    <nct_id>NCT04828083</nct_id>
  </id_info>
  <brief_title>Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty</brief_title>
  <acronym>ACBSL</acronym>
  <official_title>The Efficacy of Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty: a Randomized, Double-blinded, Non-inferiority Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhode Island Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are evaluating the postoperative outcomes in patients undergoing total knee&#xD;
      arthroplasty that receive either systemic lidocaine or ultrasound-guided adductor canal block&#xD;
      as part of their anesthetic plan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients scheduled to have total knee arthroplasty will typically receive a single shot&#xD;
      adductor canal block to serve as the primary anesthetic and as part of a multi-modal&#xD;
      post-operative analgesic plan. The use of adductor canal block is still limited to where&#xD;
      trained anesthesiologists in regional anesthesia are available. There are other nonopioid&#xD;
      analgesic adjuncts, such as Lidocaine, which is is widely available and is a very commonly&#xD;
      used local anesthetic. A major advantage of lidocaine is that it is not associated with a&#xD;
      significant side effect profile. Intravenous lidocaine which can be administered during&#xD;
      surgery and/or after surgery has demonstrated anti-inflammatory effects and can significantly&#xD;
      decrease the reliance on opioid use for adequate pain management in abdominal and spine&#xD;
      surgeries. The addition of systemic lidocaine infusion as part of a multimodal analgesia&#xD;
      strategy to minimize opioid related side effects might prove to be a useful combination for&#xD;
      clinicians where adductor canal blocks are not a viable option. However, the level of&#xD;
      evidence comparing the efficacy of intravenous lidocaine versus adductor canal block to&#xD;
      reduce postoperative opioid consumption in patients undergoing TKA is limited. We&#xD;
      hypothesized that there will be no meaningful clinical difference between systemic lidocaine&#xD;
      and ultrasound-guided adductor canal block in the 24-hour postoperative analgesia period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Postoperative opioid consumption will be converted to equivalent dose of oral morphine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>up to 2 hours (post anesthesia recovery unit), 6 hours, 12 hours, and 24 hours after surgery.</time_frame>
    <description>Patients were asked to rate their pain score during activity on a 11-point scale (0 = no pain to 10 = excruciating pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Recovery</measure>
    <time_frame>24 hours</time_frame>
    <description>The QoR-15 questionnaire has 15 questions that assess patient-reported quality of a patient's postoperative recovery using a 11-point numerical rating scale that leads to a minimum score of 0 (poor recovery) and a maximum score of 150 (excellent recovery).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Arthroplasty, Replacement, Knee</condition>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Ultrasound-guided adductor canal block with local anesthetic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single shot Ultrasound-guided adductor canal block with 0.5% ropivacaine 30 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultrasound-guided adductor canal block with saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Single shot Ultrasound-guided adductor canal block with 30 mL of normal saline (Sodium chloride)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine IV</intervention_name>
    <description>Intravenous lidcaine of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit</description>
    <arm_group_label>Ultrasound-guided adductor canal block with saline</arm_group_label>
    <other_name>Lidocaine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline IV</intervention_name>
    <description>Intravenous saline of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit</description>
    <arm_group_label>Ultrasound-guided adductor canal block with local anesthetic</arm_group_label>
    <other_name>Sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA PS 1-3 patients undergoing primary, unilateral total knee arthroplasty&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA PS classification of 4 or greater&#xD;
&#xD;
          -  Pre-existing neuropathy&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Chronic opioid consumption (&gt;3 months)&#xD;
&#xD;
          -  Infection at the site&#xD;
&#xD;
          -  Known allergy to study medications (lidocaine)&#xD;
&#xD;
          -  High grade atrioventricular block (cardiac conduction system impairment)&#xD;
&#xD;
          -  A history of CVA/TIA&#xD;
&#xD;
          -  Currently using lidocaine patches&#xD;
&#xD;
          -  Known liver disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Cohen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rhode Island Hospital, Brown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Cohen, M.D.</last_name>
    <phone>401-444-4943</phone>
    <email>alexander.cohen@lifespan.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Cohen, M.D.</last_name>
      <phone>401-444-4943</phone>
      <email>alexander.cohen@lifespan.org</email>
    </contact>
    <contact_backup>
      <last_name>Mark Kendall, M.D.</last_name>
      <phone>401-444-4722</phone>
      <email>mark.kendall@lifespan.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1093/bjaed/mkw008</url>
    <description>Intravenous lidocaine for acute pain: an evidence-based clinical update</description>
  </link>
  <reference>
    <citation>Lewis GN, Rice DA, McNair PJ, Kluger M. Predictors of persistent pain after total knee arthroplasty: a systematic review and meta-analysis. Br J Anaesth. 2015 Apr;114(4):551-61. doi: 10.1093/bja/aeu441. Epub 2014 Dec 26. Review.</citation>
    <PMID>25542191</PMID>
  </reference>
  <reference>
    <citation>Grevstad U, Mathiesen O, Valentiner LS, Jaeger P, Hilsted KL, Dahl JB. Effect of adductor canal block versus femoral nerve block on quadriceps strength, mobilization, and pain after total knee arthroplasty: a randomized, blinded study. Reg Anesth Pain Med. 2015 Jan-Feb;40(1):3-10. doi: 10.1097/AAP.0000000000000169.</citation>
    <PMID>25376972</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

